Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study.
Smith
Nicholas L
NL
Department of Epidemiology, University of Washington, and Seattle Epidemiologic Research and Information Center of the Department of Veterans Affairs Office of Research and Development, Seattle, WA
Wiley
Jennifer R
JR
Legault
Claudine
C
Rice
Kenneth M
KM
Heckbert
Susan R
SR
Psaty
Bruce M
BM
Tracy
Russell P
RP
Cushman
Mary
M
D000941:Antigens / Q000187:drug effects; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005167:Factor VII / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011374:Progesterone / Q000009:adverse effects*; D011446:Prospective Studies; D011486:Protein C / Q000187:drug effects
D000941:Antigens; D004966:Estrogens, Conjugated (USP); D017395:Plasminogen Activator Inhibitor 1; D011486:Protein C; C042580:factor VII clotting antigen; D011374:Progesterone; D005167:Factor VII; D017258:Medroxyprogesterone Acetate